Galeterone - Eledon Pharmaceuticals
Alternative Names: TOK-001; VN/124; VN/124-1Latest Information Update: 22 Mar 2023
At a glance
- Originator Tokai Pharmaceuticals
- Developer Novus Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Androgen receptor antagonists; Androgen receptor degradation enhancers; Steroid 17-alpha-hydroxylase inhibitors; Ubiquitin thiolesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 13 Mar 2023 LTN Pharm terminates a phase II ARMOR2 trial in Prostate Cancer (Hormone refractory) (PO) in the US and Canada upon recommendation from the study's Data Monitoring Committee and lack of efficacy (NCT01709734)
- 04 Jan 2021 Novus Therapeutics is now called Eledon Pharmaceuticals
- 09 Aug 2017 Discontinued - Phase-I for Prostate cancer (Treatment-resistant) in USA (PO)